Thu, Dec 25, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Rubicon takes legal aim at hedge fund launch by former Co-CIO Attias

Thursday, August 04, 2011
Opalesque Industry Update – In early July Tim Attias, former co-chief investment officer of Rubicon Fund Management, announced he would launch Sata Partners along with Catherine Cripps former head of research at Man Investments. On Thursday this week, Rubicon Fund Management, Attias’ former employer announced that it has issued legal proceedings against both Attias and former fund manager Santiago Alarco.

According to a statement released by Rubicon, “The claim includes allegations that Alarco and Attias conspired and acted in breach of their covenants and fiduciary duties to Rubicon whilst still in its employ.”

eFinancialNews which reported the launch in early July said that Alarco was on garden leave from the firm, which typically means they are being paid and have agreed not to work, and are limited in their ability to join a competitor for a specific amount of time. The report said that Attias, Cripps and GAM declined to comment.

Aside from trying to prove that Rubicon should be awarded “Declaratory Relief, Injuncion and Damages and Account of profits and costs, the firm is also obviously feeling stung by the recent announcement of Attias’ launch (the Rubicon statement also seeks to correct media reports about the management of the funds that were included in announcements about Attias’ new firm).

In some of the launch stories Rubicon’s performance was reportedly “It returned 44% in 2008, 15% in 2009 and 14% last year, according to a person familiar with the situation.” In other stories “Under Attias’ watch, the Rubicon Global hedge fund delivered returns of 44% in 2008, 15% in 2009 and 14% in 2010, on assets of $1.65 billion.”

In today’s statement Rubicon says: “According to the Hedge Fund Intelligence Global Review, Rubicon Global Fund was the top performing Global Macro Fund for the three years from January 2008 to December 2010 with a total return over the three years of 91.23%.

The bulk of this return was obtained in 2008, which was a very difficult year for all investors. In 2008 Rubicon provided investors a return of 44.80%. Paul Brewer, CIO, provided two thirds of the 2008 return. Rubicon has provided investors a compound annual rate of return in excess of 13%.

The spokesman added, “Paul Brewer, the man who built Rubicon, is now very much back in the driving seat and is determined to protect the interests of investors and Rubicon’s reputation.”

Kirsten Bischoff

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its